Our team is one of the 2 teams of STROMALab unit certified by the university, Inserm, and EFS. Our common goal is the study and therapeutic use of stromal cells of 2 tissues: bone marrow and adipose tissue. Bone marrow is considered here as a paradigm for understanding the functions of mesenchymal stem / stromal cells (MSCs), the relationships of MSCs with their microenvironment, and the adaptations necessary for their clinical use.
Seventeen people form the scientific backbone of our team, forming strong links with animal testing and clinical trials. We are an integral part of the SFR Biology Health Toulouse and have access to all Genotoul platforms.
We are one of the French and European teams with a major expertise on the biology of mesenchymal stem / stromal cells of the bone marrow and adipose tissue, expertise put at the service of regenerative medicine for bone repair, the treatment of vascular pathologies and inflammatory pathologies.
Our studies focus on understanding the heterogeneity of MSCs within tissues and in culture, as well as their relationship to the different components of their tissue environment in vivo, both physico-chemical factors (hypoxia) and innate immune cells.
We have thus been able to describe different roles of MSCs in the regulation of bone physiology, whether through the expression of the HLA-G molecule or by that of CD200. Our studies show that during the dialogue between macrophages and MSCs, macrophages in turn modulate the immunosuppressive capacities of MSCs. The study of different populations under conditions close to those encountered in vivo, in particular the low O2 tension, makes it possible to better understand the role of MSCs in vivo. Thanks to an innovative approach, we found within MSCs, a sub-population of more immature cells with stem cell characteristics.
All of our work leads to the redefinition of MSC culture techniques that by our direct link with the production laboratory of CSM can be set up under conditions of good manufacturing practice (GMP) essential for the production of medicines Innovative Therapy (MTI) for clinical trials.
We hold several patents and the development of our know-how is valued through partnerships with the industry.
Expected health benefits:
Our studies will help understand the role of different subpopulations of MSCs within tissues and their interactions with innate immunity in regenerative processes.
This is already reflected in our participation as coordinator or co-coordinator in 4 European programs, 3 of the 7th CPRD: CASCADE, ADIPOA and REBORNE, and one of H2020: ADIPOA2 and also our participation in hospital clinical research programs. (PHRC): MESAMI and ACELLDREAM. These programs cover fields ranging from orthopedics (non-union and necrosis of the femoral head) and rheumatology (knee osteoarthritis) to ischemic pathologies (myocardial infarction and critical ischemia of the lower limbs) and dysimmune diseases (scleroderma). The direct links from basic research to the clinic, through our R & D activities, will allow the improvement of MSC culture processes in order to make their action more effective in regenerative medicine programs in humans.
5 teachers researchers
6 technical support
4 PhD students and 1 post-doctoral position